Vanda Pharmaceuticals (VNDA) has received a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use regarding iloperidone for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the regulator said Friday.
The EMA recommended the refusal of marketing authorization for iloperidone and said Vanda may apply for a re-examination of the opinion within 15 days.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.